FDA Approves Enhertu for HER2-Low Metastatic Breast Cancer
The approval came more quickly than expected by AstraZeneca and is based on data showing Enhertu reduced the risk of progression or death versus chemo by nearly 50 percent.
Valo Therapeutics Advancing Plans for Oncolytic Virus Treatments With Tailored Immunogenic Peptides
Premium
The company hopes to establish proof of concept for its PeptiCRAd-1 therapy in a Phase I trial and then work on individualizing it to a patient's tumor antigen profile.
In new guidelines, an expert panel recommended IHC and PCR for certain cancer types and pointed out knowledge gaps supporting NGS in other settings.
During a call to discuss Q2 financials, the company reported a 13 percent year-over-year decrease in Rubraca revenues and said it is exploring strategies to raise additional capital.
The drug contributed $77 million in revenues during the quarter, but the company said that many NSCLC patients aren't receiving results in time for treatment decisions.
Massey Cancer Center Researchers Exploring SHP2 Inhibitor Potential in Pediatric Neuroblastoma
Premium
Based on data from tumor models, researchers are working with the NCI to explore the potential of SHP2 inhibitors with maintenance therapy in high-risk neuroblastoma with NF1 loss.
The firm reported strong revenue increases for its antibody-drug conjugate Trodelvy and its cell therapies Yescarta and Tecartus, offsetting losses outside oncology.